Integrated Care Centers to Improve HIV Outcomes in Vulnerable Indian Populations
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
![](https://webarchive.library.unt.edu/web/20130315211255im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
This is a cluster randomized trial to evaluate the effectiveness of integrated care centers (ICC) to improve access to HIV testing, prevention services, and treatment among high-risk populations of injection drug users (IDU) and men who have sex with men (MSM) in India. We will collect baseline ethnographic and survey data from approximately 27 IDU or MSM sites in India. We will use baseline data to select 22 sites for the trial (12 IDU and 10 MSM) and to stratify sites according to key baseline characteristics. We will perform stratified randomization to assign sites to either the ICC intervention or to standard services. ICCs, which will be either IDU or MSM-focused, will provide an accepting atmosphere in which members of vulnerable groups can drop-in, receive rapid HIV voluntary counselling and testing, risk reduction counseling and services, and antiretroviral therapy. ICCs will be scaled-up from existing governmental or non-governmental organizations and services provided at ICCs will be supported by the National AIDS Control Organization (NACO) of India. After providing services in communities for two years, we will conduct an evaluation survey (with biological and behavioral measures) of approximately 1000 subjects in the target populations in each of the 22 study sites. Integrated care centers have the potential to improve access to HIV prevention and treatment services among vulnerable, high-risk populations.
Condition | Intervention | Phase |
---|---|---|
HIV Infection |
Behavioral: Integrated care centers |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Health Services Research |
Official Title: | A Cluster Randomized Trial of Integrated Care Centers to Improve Access to HIV Prevention, Testing, and Treatment Services Among High-Risk Vulnerable Populations in India |
- Proportion reporting HIV testing in the prior 12 months [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion of HIV-infected participants aware of status [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion of HIV-infected participants visiting an HIV treatment provider in prior 6 months [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion of ART-eligible HIV-infected participants using ART [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Community viral load [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]Average log(10) HIV RNA concentration among HIV-infected participants
- Proportion of HIV-infected participants with suppressed HIV RNA [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Prevalence of recent HIV infection [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion of IDU reporting needle or syringe sharing [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion of IDU reporting drug abstinence [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion reporting unprotected vaginal/anal intercourse [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Number of non-main male partners in prior 6 months in MSM [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion reporting substance abuse among MSM [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion with depressive symptoms [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Number of unprotected sexual acts reported by MSM [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Perceived and experienced stigma [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
- Proportion reporting spouse tested for HIV [ Time Frame: Measured in Baseline and Evaluation (~ 2 years later) Surveys ] [ Designated as safety issue: No ]
Estimated Enrollment: | 49000 |
Study Start Date: | October 2012 |
Arms | Assigned Interventions |
---|---|
Experimental: Integrated care centers
Integrated care centers will provide HIV prevention and treatment services to high risk populations of IDU or MSM in an accepting and supportive environment.
|
Behavioral: Integrated care centers |
No Intervention: Standard services
In Standard Services sites, HIV testing, prevention, and treatment services will be available through standard venues. Government centers typically provide most HIV testing services and are the only source for free antiretroviral therapy. Non-governmental organizations typically provide prevention and risk reduction services.
|
![](https://webarchive.library.unt.edu/web/20130315211255im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Key Informant Interviews:
Persons may be included in the key informant interviews if they meet all of the following criteria:
- 18 years of age or older
- Knowledge of the local HIV risk group of interest (IDU or MSM)
- Psychologically fit to participate in the study and to understand the consent
- Ability to comprehend one of the consent translation languages
- Provide informed consent
Focus groups:
Persons may be included in the focus groups if they meet all of the following criteria:
- 18 years of age or older
Member of a target HIV risk group, meeting criterion 2a or 2b
- IDU: self-reported injection drug use in prior 12 months
- MSM: self-identify as male and report oral/anal sex with another male in prior 12 months
- Psychologically fit to participate in the study and to understand the consent
- Ability to comprehend one of the consent translation languages
- Provide informed consent
Baseline or evaluation respondent-driven sampling (RDS) survey
Persons may be included in the baseline or evaluation RDS survey if they meet all of the following criteria:
- 18 years of age or older
Member of a target HIV risk group, meeting criterion 2a or 2b
- IDU: self-reported injection drug use in prior 24 months
- MSM: self-identify as male and report oral/anal sex with another male in prior 12 months
- Psychologically fit to participate in the study and to understand the consent
- Ability to comprehend one of the consent translation languages
- Present a valid RDS referral coupon (unless a seed)
- Provide informed consent
Exclusion Criteria:
Key Informant Interviews:
Persons will be excluded from the key informant interviews if they meet any of the following criteria:
- Younger than 18 years
- Do not have knowledge of the local HIV risk group of interest (IDU or MSM)
- Are not psychologically fit to participate in the study or to understand the consent
- Do not have ability to comprehend one of the consent translation languages
- Do not provide informed consent
Focus groups:
Persons will be excluded from the focus groups if they meet any of the following criteria:
- Younger than 18 years
Are not a member of a target HIV risk group, meeting neither criterion 2a nor 2b
- IDU: self-reported injection drug use in prior 12 months
- MSM: self-identify as male and report oral/anal sex with another male in prior 12 months
- Are not psychologically fit to participate in the study or to understand the consent
- Do not have ability to comprehend one of the consent translation languages
- Do not provide informed consent
Baseline or evaluation RDS survey
Persons will be excluded in the baseline or evaluation RDS survey if they meet any of the following criteria:
- Younger than 18 years
Are not a member of a target HIV risk group, meeting neither criterion 2a nor 2b
- IDU: self-reported injection drug use in prior 24 months
- MSM: self-identify as male and report oral/anal sex with another male in prior 12 months
- Are not psychologically fit to participate in the study or to understand the consent
- Do not have ability to comprehend one of the consent translation languages
- Do not present a valid RDS referral coupon and are not a seed
- Do not provide informed consent
![](https://webarchive.library.unt.edu/web/20130315211255im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
Contact: Shruti Mehta, PhD | 443-287-3837 | shmehta@jhsph.edu |
India | |
YR Gaitonde Center for AIDS Research and Education | Recruiting |
Chennai, Tamil Nadu, India, 600113 | |
Contact: Aylur Srikrishnan, BA 91+22542929 krish@yrgcare.org |
Principal Investigator: | Gregory M Lucas, MD | Johns Hopkins University |
Principal Investigator: | Shruti Mehta, PhD | Johns Hopkins University |
Principal Investigator: | David D Celentano, ScD | Johns Hopkins University |
Principal Investigator: | Suniti Solomon, MD | YR Gaitonde Center for AIDS Research and Education |
Principal Investigator: | Aylur Srikrishnan, BA | YR Gaitonde Center for AIDS Research and Education |
Principal Investigator: | Suresh Kumar, MPH | YR Gaitonde Center for AIDS Research and Education |
Principal Investigator: | Sunil S Solomon, PhD | Johns Hopkins University |
![](https://webarchive.library.unt.edu/web/20130315211255im_/http://clinicaltrials.gov/ct2/html/images/frame/triangle.gif)
No publications provided
Responsible Party: | Gregory M. Lucas, Associate Professor of Medicine, Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT01686750 History of Changes |
Other Study ID Numbers: | R01DA032059, R01DA032059, R01MH089266 |
Study First Received: | September 13, 2012 |
Last Updated: | November 22, 2012 |
Health Authority: | United States: Institutional Review Board United States: Data and Safety Monitoring Board India: Indian Council of Medical Research India: Institutional Review Board United States: Federal Government |
Keywords provided by Johns Hopkins University:
HIV injection drug use men who have sex with men voluntary counselling and testing |
risk reduction sexually transmitted infections community viral load antiretroviral therapy |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
ClinicalTrials.gov processed this record on March 14, 2013